Anti-Rat Fractalkine (Clone 96834)
| Code | Size | Price |
|---|
| LEI-C1438-25ug | 25 ug | £375.00 |
Quantity:
| LEI-C1438-500ug | 500 ug | £773.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG1
Antibody Clonality: Monoclonal
Antibody Clone: 96834
Regulatory Status: RUO
Target Species: Rat
Application: Western Blot (WB)
Shipping:
Ambient
Storage:
The lyophilized antibody can be stored desiccated at -20°C to -70°C for up to twelve months. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid repeated freeze thaw cycles. No detectable loss of activity was observed after six months.
Further Information
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This monoclonal antibody has been 0.2 um filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.3 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.
Formulation:
This monoclonal antibody has been 0.2 um filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.3 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.
Immunogen:
E. coli-Derived Recombinant Rat CX3CL1, Chemokine Domain
Long Description:
Fractalkine (FKN) is a transmembrane mucin-chemokine hybrid molecule expressed on activated endothelium1 that mediates attachment and firm adhesion of T cells, monocytes and NK cells.2 FKN plays an important proinflammatory role in rheumatoid arthritis (RA) pathogenesis as characterized by induction of synovial angiogenesis, chemotaxis, activation of monocytes and T cells as well as the stimulation of proliferation and synthesis of matrix degrading enzymes (matrix metalloproteinases, MMP) in synovial fibroblasts. Fractalkine thus may represent a novel target molecule for therapeutic intervention in RA.3 FKN is also an essential biomarker for predicting the prognosis of patients with colorectal cancer (CRC).4
Target:
Fractalkine
References
1. Patel, DD. et al. (1998)J Exp Med. 188: 1413
2. Hwang, ST. et al. (1999)Eur J Immunol. 29: 2551
3. Muller, GA. et al. (2008)Z Rheumatol. 67: 424
4. Mori, M. et al. (2005)Int J Oncol. 26: 41